Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
Lung Cancer (Amsterdam, Netherlands)|July 24, 2018
Effects of crizotinib on creatinine clearance and renal hemodynamicsLysbert Meijer-Schaap, John W G Van Putten, Wilbert M T JanssenLung Cancer (Amsterdam, Netherlands)|July 13, 2004
Phase II study of docetaxel and carboplatin as second-line treatment in NSCLCFloris M Wachters, John W G van Putten, H Marike Boezen, et al.Journal of Medical Case Reports|September 29, 2022
Acute kidney injury and long-term renal effects of alectinib in anaplastic lymphoma kinase-positive non-small cell lung carcinoma: a case reportMarco van Londen, Elizabeth Roosma, Stefanie Vogels, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2007
Iris metastasis in small-cell lung carcinomaAnke W J Roenhorst, Alphons C M van den Bergh, John W G van Putten, et al.Respiratory Medicine|February 18, 2005
Technical description of endoscopic ultrasonography with fine-needle aspiration for the staging of lung cancerHenk Kramer, John W G van Putten, W Rob Douma, et al.International Journal of Radiation Oncology, Biology, Physics|September 6, 2003
Selective targeting of homologous DNA recombination repair by gemcitabineFloris M Wachters, John W G van Putten, Jan G Maring, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
A Phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancerJohn W G van Putten, Allen Price, Annya H D van der Leest, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 19, 2002
Comparison of (11)C-choline and (18)F-FDG PET in primary diagnosis and staging of patients with thoracic cancerRemge M Pieterman, Tjin H Que, Philip H Elsinga, et al.Pharmacoepidemiology and Drug Safety|December 9, 2020
Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in extensive disease small cell lung cancerChristine M Cramer-van der Welle, Franz M N H Schramel, Bas J M Peters, et al.Plos One|August 8, 2013
Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcomeGerald S M A Kerner, Ed Schuuring, Johanna Sietsma, et al.Pageof 2